We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAldeyra The

Aldeyra The

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.6107 USD -0.04 ( 6.25%)
Last update at 2026-11-12T15:57:00Z
VOLUME
194804
Market Cap
82.65M

Momentum Score

…

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.60
Low
0.66
High
52 Week Price Range
1.07
Low
5.93
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aldeyra Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that target aldehyde-mediated inflammatory pathways for immune and ocular diseases. Long-term growth drivers include clinical trial progress, potential regulatory approvals, and partnerships or commercialization of its platform across multiple indications, which may appeal to investors seeking exposure to a mechanism-driven pipeline.

Key risks are clinical and regulatory setbacks, substantial cash burn with likely need for additional financing and shareholder dilution, and strong competition in inflammatory and ophthalmic markets.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.65
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.35
ROE
-49.48%
Net Debt
-54.51M
ROCE
-72.18%
Diluted EPS TTM
-0.36

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -33.85M -55.85M -37.54M -62.02M -57.78M
Net income -33.85M -55.85M -37.54M -61.37M -59.25M
Selling general administrative 9602351.00M 11.89M 13.34M 15.37M 11.28M
Selling and marketing expenses - - 0.26M - -
Gross profit -0.25M -0.25M -0.26M - -
Reconciled depreciation 0.25M 0.25M 0.26M 0.26M 0.26M
Ebit -31.94M -53.93M -35.47M -62.68M -56.22M
Ebitda -31.69M -53.68M -35.21M -60.33M -56.03M
Depreciation and amortization 0.25M 0.25M 0.26M 2.35M 0.19M
Non operating income net other - - - 2.35M 0.19M
Operating income -35.27M -60.12M -42.79M -62.68M -56.22M
Other operating expenses 35.27M 60.12M 42.79M 62.68M 56.22M
Interest expense 1.91M 1.93M 2.07M 1.69M 1.74M
Tax provision - - - - 0.00M
Interest income 3.32M 6.19M 6.72M 2.35M 0.19M
Net interest income 1.42M 4.27M 4.70M 0.66M -1.56M
Income tax expense - -55851444.00M - -0.66M 1.48M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 35.01M 60.12M 42.79M 62.68M 56.22M
Cost of revenue 0.25M 0.25M 0.26M - -
Total other income expense net 1.42M 4.27M 5.25M 0.66M -1.56M
Net income from continuing ops -33.85M -55.85M -45.69M -62.02M -57.78M
Net income applicable to common shares - - - -62.02M -57.78M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 72.06M 104.61M 148.33M 181.29M 233.14M
Other current assets 1.74M 2.92M 0.52M 6.72M 2.96M
Total liab 27.81M 33.60M 28.53M 30.28M 27.40M
Total stockholder equity 44.25M 71.00M 119.80M 151.01M 205.74M
Other current liab 6.12M 12.12M -0.46M 14.07M 10.52M
Common stock 0.06M 0.06M 0.06M 0.06M 0.06M
Capital stock 0.06M 0.06M 0.06M 0.06M 0.06M
Retained earnings -483.96M -450.11M -394.26M -356.72M -294.69M
Other assets - 2.21M 0.00M - -
Cash 70.04M 54.53M 142.82M 144.42M 229.79M
Total current liabilities 27.81M 18.60M 22.26M 15.36M 11.77M
Current deferred revenue 6.00M 6.00M 6.00M - -
Net debt -54.51M -39.22M -127.17M -128.34M -213.93M
Short term debt 15.53M 0.30M 15.39M 1.16M 0.23M
Short long term debt 15.25M 0.03M 15.15M 0.91M -
Short long term debt total 15.53M 15.30M 15.66M 16.08M 15.86M
Other stockholder equity 528.15M 521.02M 513.99M 507.77M 500.37M
Property plant equipment - - - 0.02M 0.03M
Total current assets 71.78M 104.07M 143.35M 181.02M 232.75M
Net tangible assets - - - 151.01M 205.74M
Short term investments 0.00M 46.62M 0.00M 29.88M 0.00M
Net receivables - - - 3.24M 125.00M
Long term debt - 15.00M - 14.92M 15.50M
Inventory - - - -3.24M -
Accounts payable 0.16M 0.18M 1.34M 0.13M 1.02M
Accumulated other comprehensive income - 0.04M 0.00M -0.10M -
Common stock total equity - - - 0.06M 0.06M
Retained earnings total equity - - - -356.72M -294.69M
Non currrent assets other - 0.27M 4.46M 0.25M 0.35M
Non current assets total 0.28M 0.53M 4.98M 0.27M 0.38M
Capital lease obligations 0.28M 0.27M 0.51M 0.25M 0.35M
Long term debt total - - - 14.92M 15.50M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 47.74M -44.92M 57.00M -29.94M -0.01M
Change to liabilities - - - 0.32M 5.20M
Total cashflows from investing activities 47736288.00M -44.92M 30.00M -29.95M -0.01M
Net borrowings 0.00M -0.29M -1.04M - -
Total cash from financing activities 1123556.00M -0.17M -1.27M 1.22M 194.50M
Change to operating activities - - - -2.56M 6.80M
Net income -33846661.00M -55.85M -37.54M -62.02M -57.78M
Change in cash 15514162.00M -88.30M -1.60M -85.37M 151.93M
Begin period cash flow 54527092.00M 142.82M 144.42M 229.79M 77.86M
End period cash flow 70041254.00M 54.53M 142.82M 144.42M 229.79M
Total cash from operating activities -33345682.00M -43.21M -30.33M -56.64M -42.56M
Issuance of capital stock - - - 0.00M 189.81M
Depreciation -897557.00M 0.25M 0.26M 0.26M 0.26M
Other cashflows from investing activities - -51999948.00M - - -
Sale purchase of stock - - -0.53M 1.22M 194.50M
Other cashflows from financing activities 1123554.88M 0.12M -0.53M 0.10M 4.68M
Change to netincome - - - 8.29M 7.11M
Capital expenditures 0.00M 0.00M 0.00M 0.02M 0.01M
Cash flows other operating - - - -3.76M 2.24M
Cash and cash equivalents changes - - - -85.37M 151.93M
Change in working capital -5.18M 5.91M 0.86M -3.44M 7.44M
Stock based compensation 6091413.00M 7.97M 5.75M 8.29M 7.11M
Other non cash items -4692871.82M -1.49M 0.34M 0.28M 0.41M
Free cash flow -33345682.00M -43.21M -30.33M -56.65M -42.56M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ALDX
Aldeyra The		 -0.04
6.25%		 0.61 - - - 2.34 6.96
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Aldeyra The

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

131 Hartwell Avenue, Lexington, MA, United States, 02421

781 761 4904

https://www.aldeyra.com

6

Name Title Year Born
Dr. Todd C. Brady M.D., Ph.D. CEO, Pres & Director 1972
Dr. Stephen G. Machatha Ph.D. Chief Devel. Officer 1977
Mr. Bruce Greenberg CPA, M.B.A. VP of Fin., Interim CFO & Treasurer NA
Mr. Kelly Mizer VP of Commercial Strategy & Operations NA
Dr. Todd C. Brady M.D., Ph.D. CEO, President & Director 1972
Mr. Bruce Greenberg CPA, M.B.A. Senior VP of Finance, Interim CFO & Treasurer 1968
Dr. Stephen G. Machatha Ph.D. Chief Development Officer 1977
Mr. Kelly Mizer Vice President of Commercial Strategy & Operations NA
David Burke Head of Investor Relations NA
Mr. Michael Alfieri Principal Financial & Accounting Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…